3rd Quarter 2024
Key topics in this quarter’s edition include:
- Marstacimab - To prevent or reduce the frequency of bleeding episodes in individuals with hemophilia A or hemophilia B without inhibitors
- Inavolisib - In combination with Ibrance (palbociclib) and fulvestrant, for the treatment of patients with PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment
- Acoramidis - Treatment of cardiomyopathy due to transthyretin-mediated amyloidosis